University of Cambridge, Medical Research Council Cancer Cell Unit, Hutchison/MRC Research Centre, Hills Road, Cambridge CB2 0XZ, United Kingdom.
University of Cambridge, Medical Research Council Cancer Cell Unit, Hutchison/MRC Research Centre, Hills Road, Cambridge CB2 0XZ, United Kingdom.
Mol Oncol. 2014 Mar;8(2):161-8. doi: 10.1016/j.molonc.2013.10.005. Epub 2013 Nov 6.
Chromosomal instability is a hallmark of human cancer cells, but its role in carcinogenesis remains poorly resolved. Insights into this role have emerged from studies on the tumour suppressor BRCA2, whose inactivation in human cancers causes chromosomal instability through the loss of essential functions of the BRCA2 protein in the normal mechanisms responsible for the replication, repair and segregation of DNA during cell division. Humans who carry heterozygous germline mutations in the BRCA2 gene are highly predisposed to cancers of the breast, ovary, pancreas, prostate and other tissues. Here, we review recent studies that describe genetically engineered mouse models (GEMMs) for pancreatic cancer associated with BRCA2 mutations. These studies not only surprisingly show that BRCA2 does not follow the classical Knudson "two hit" paradigm for tumour suppression, but also highlight features of the interplay between TP53 inactivation and carcinogenesis in the context of BRCA2 deficiency. Thus, the models reveal novel aspects of cancer evolution in carriers of germline BRCA2 mutations, provide new insights into the tumour suppressive role of BRCA2, and establish valuable new preclinical settings for testing approaches to pancreatic cancer therapy; together, these features emphasize the value of GEMMs in cancer research.
染色体不稳定性是人类癌细胞的一个标志,但它在癌症发生中的作用仍未得到很好的解决。对肿瘤抑制因子 BRCA2 的研究揭示了这一作用,BRCA2 的失活会导致人类癌症中的染色体不稳定性,这是由于 BRCA2 蛋白在正常的复制、修复和细胞分裂过程中 DNA 分离机制中丧失了重要功能。携带 BRCA2 基因突变的人类易患乳腺癌、卵巢癌、胰腺癌、前列腺癌和其他组织的癌症。在这里,我们回顾了最近描述与 BRCA2 突变相关的胰腺癌的基因工程小鼠模型 (GEMMs) 的研究。这些研究不仅令人惊讶地表明 BRCA2 不符合经典的 Knudson“两次打击”肿瘤抑制范式,而且还强调了在 BRCA2 缺陷背景下,TP53 失活与癌症发生之间相互作用的特征。因此,这些模型揭示了携带胚系 BRCA2 突变的个体中癌症进化的新方面,为 BRCA2 的肿瘤抑制作用提供了新的见解,并为胰腺癌治疗方法的测试建立了有价值的新临床前环境;这些特征共同强调了 GEMMs 在癌症研究中的价值。